Interferon β preparations are widely used to treat multiple sclerosis (MS) or clinically isolated syndrome (CIS). Overall, up to 40% of patients will eventually develop antibodies against interferon β, 6-9 of which a significant proportion neutralize the biological activity of interferon β (neutralizing antibodies, NAbs). 10, 11 Several factors related to either the interferon β compound and administration or the individual patient influence immunogenicity. 6, [12] [13] [14] In two previous studies on German MS 15, 16 In addition, an association of HLA-DRB1*07:01 with ADAs was described for 39 American patients. 17 A study conducted on 610 Spanish patients reported an increased risk of developing NAbs for the combined presence of the haplotype HLA-DRB1*07:01 with the HLA class I alleles HLA-A*26 and HLA-B*14 and replicated the association of DRB1*04:01. 18 In a Swedish analysis, the HLA-DRB1*15 and HLA-DQA1*05 alleles were associated with an increased risk for developing NAbs in patients treated with interferon β-1a, 19 while HLA-DRB1*04 was nominally associated in patients receiving interferon β-1b. In a genome-wide association study (GWAS) on German patients, two single-nucleotide polymorphisms (SNPs), rs9272105 (linked to the HLA class II locus) and rs4961252 (linked to an intergenic region on chromosome 8), were significantly associated with ADA titers. 20 The aim of this study was to validate these genetic markers in the setting of two multi-national phase III trials conducted on patients treated with interferon β-1b and carefully monitored for the occurrence of ADA.
Methods

Patient cohorts
Patients were treated with interferon β-1b in two phase III trials. These studies were the BEtaseron ® / BEtaferon ® in Newly Emerging multiple sclerosis For Initial Treatment trial (BENEFIT; clinicaltrials.gov ID: NCT00185211) 21 and the Betaferon ® Efficacy Yielding Outcomes of a New Dose trial (BEYOND; clinicaltrials.gov ID: NCT00099502). 22 In BENEFIT, 478 CIS patients were randomized to interferon β-1b 250 μg, administered subcutaneously every other day, or placebo (5:3 ratio). Patients received placebo for 2 years or until MS was diagnosed using the Poser criteria. 23 Patients were then offered interferon-β-1b for up to 5 years. In BEYOND, 2244 patients with relapsing-remitting multiple sclerosis (RRMS) were randomized in a 2:2:1 ratio to receive interferon β-1b 500 μg, interferon β-1b 250 μg, both administered subcutaneously every other day, or glatiramer acetate 20 mg, administered subcutaneously daily for a period of 2 or up to 3.5 years. Details of the study protocols and results of NAb testing were published elsewhere. 22, [24] [25] [26] In the analyses presented in this manuscript, we included patients who had given informed consent for genetic testing and who were treated with interferon β-1b for at least 6 months with a dose of either 250 μg (n = 567) or 500 μg (n = 374). This dose was included as a covariate in the analyses. Because ADA development usually occurs within the first year of treatment, 27 genetic association analyses were restricted to patients who had either received interferon β-1b for at least 6 months and showed a positive NAb result or who had continuously received interferon β-1b for at least 12 months, irrespective of NAb status. Patients with missing information in clinical covariates as well as genetic outliers were excluded, leading to a final number of 941 patients included in the analyses after quality control (QC).
Measurement of antibodies against interferon β
In both clinical trials, serum samples were collected at baseline and every 6 months after that to evaluate anti-interferon β-1b antibodies using the myxovirus protein A (MxA) induction assay. 28 Measurement of anti-interferon β-1b antibodies was conducted in the same laboratory for both clinical trials (Rentschler Biotechnologie GmbH, Laupheim, Germany). A titer of 20 normalized units (NUs)/mL was used as a cutoff between NAb negativity and positivity. Patients without a NAb-positive sample and with either a treatment interruption of more than 90 days in the first treatment year or with a missing NAb measurement at year 1 and later were excluded from the analyses.
Study endpoints
The predefined primary endpoint (EP) was the presence of NAbs at any time during the studies (EP1). This EP was analyzed in all eligible patients. Secondary EPs were mean NAb titer (EP2), the area under the NAb curve (NAb AUC) of four measurements performed during the first two treatment years (EP3), the maximum NAb titer during the first 2 years (EP4), and time to first NAb presence (EP5). EP5 was assessed in NAb-positive patients only. Because the duration of the BENEFIT trial was longer than the BEYOND trial, EP3 and EP4 potentially differed systematically between the studies. To prevent bias in these EPs, EP3 and EP4 were only assessed during the first 2 years of either study. In addition to the examination of candidate variants, a hypothesis-free GWAS was conducted for each EP as an explorative analysis.
Sequencing, genotyping, and imputation HLA-DRB1 alleles were sequenced by latent growth curve (LGC)-Genomics (formerly known as AGOWA) using the HLA-DRB1 AlleleSEQR/HARP kits from Abbott Molecular, Abbott Park, IL. Genotyping was conducted using the Affymetrix Genome-Wide Human SNP Array 6.0. QC steps on samples included removal of individuals with a genotyping rate <98% and of genetic outliers using EIGENSTRAT (for details see Supplementary 
Statistical analyses
For EP1, the presence of NAbs, logistic regression was used. EPs EP2-EP4 were analyzed using linear regression. A Cox proportional hazards model was used to analyze EP5 using the R package survival. 33 EPs EP2-EP4 were inverse-normally transformed to normal distributions before analysis. The following covariates were used in all analyses: study (BENEFIT/BEYOND), sex, age, interferon β-1b treatment dose (250 μg/500 μg), interferon β-1b treatment duration, and the first six multidimensional scaling (MDS) components of the genetic similarity matrix to control for population substructure (Supplementary Figure e-1). For EP5, the study was included as a stratification variable to meet the proportional hazards assumption. Test statistics were not inflated in any model (genomic inflation λ ≤ 1.025). For the analysis of candidate variants, the significance threshold α was Bonferroni-corrected for 11 tests (α = 0.0045). Because HLA-DRB1*15 and HLA-DRB1*15:01 are not independent of each other, they were not considered as separate alleles for calculation of this significance threshold. All analyses of candidate variants were conducted in R v3.2.1. The GWAS was conducted in PLINK2 v1.90b3.38 for EP1-EP4, 34 and in R for EP5. The significance threshold for the GWAS was α = 5 × 10 -8 . In addition to the analyses in the complete set of patients, EP2-EP5 were analyzed separately using the same methods and covariates within the subgroup of NAb-positive patients. The eQTL data were obtained from the Genotype-Tissue Expression (GTEx) project via the online GTEx portal (http://www.gtexportal.org/) on 13 December 2017. 35 
Results
A total of 941 patients from the BENEFIT and BEYOND trials were analyzed in this study. Of these, 361 patients developed NAbs during the trials (Table 1 ). All 941 patients had genotyping data available, while (Table 2) .
Association of candidate genetic markers with secondary EPs
We performed analyses for the three secondary EPs mean NAb titer (EP2), NAb AUC (EP3), and maximum NAb titer (EP4) using linear regression on all patients. These three measurements were highly correlated (Spearman's correlation coefficients ≥0.98, Supplementary Table e-3). Accordingly, results for EP2 (Table 3) were highly similar to EP3 and EP4 (Supplementary Tables e-5 and e-6), with quantitative differences in p-values. Qualitatively, these results were also very similar to the analysis of EP1 (Table  2 ). In addition to the variants already nominally or significantly associated with EP1, HLA-DRB1*04:08 was nominally associated with EP2 (Table 3) .
Association of candidate genetic markers in NAbpositive patients
Similar to our primary EP and previous studies, the analyses of EP2-EP4 in all patients addressed the question whether candidate markers influence the risk of developing NAbs. However, genetic variants might also influence the titer of NAbs once a patient has already developed ADA. To examine this hypothesis, we repeated the analyses in the subset of patients that developed NAbs within the first 2 years, excluding NAb-negative patients. rs9272105 were nominally associated with mean NAb titer, but no variant remained associated after correcting for multiple testing (Supplementary Tables e-7 -e-9).
EP5, time to NAb presence, was only analyzed in NAb-positive patients, using a Cox proportional hazard model. Under the hypothesis that risk alleles should decrease the time to the presence of NAbs, markers rs9272105 and HLA-DRB1*15 were nominally associated, yet no association of candidate markers remained significant after correction for multiple testing (Supplementary Table e-10) .
Explorative GWAS for all EPs
The main objective of our study was the replication of candidate variants from previous publications. However, as we had genome-wide genotyping data available for all patients, we also conducted exploratory GWAS to identify novel variants associated with the development of ADA. For EP1, the SNP showing the overall highest association was rs522308 (odds ratio (OR) = 2.60, confidence interval (CI) = 2.05- 
Discussion
Interferon β is a well-established first-line treatment in MS. Up to 40% of patients treated with interferon β developed ADA, most of them with neutralizing activity, which may antagonize the therapeutic activity of the drug. 6 Although the immunogenicity of biopharmaceuticals is a known critical phenomenon, reasons for the large inter-individual variation in the occurrence of ADA are still poorly understood. In previous studies, nine HLA-DRB1 alleles and two SNPs have been proposed to either influence the risk to develop anti-interferon β antibodies or to be associated with ADA titers. [15] [16] [17] [18] [19] [20] Six of these markers are assumed to increase the risk for ADA development, the remaining five are candidates for protection from ADA.
In this study, these genetic markers were evaluated in an independent dataset of patients with CIS or RRMS from two large international phase III clinical trials, carefully monitored for ADA titer and persistence of ADA over time. We confirmed the associations of HLA-DRB1*04:01 and HLA-DRB1*07:01 with NAb presence (Table 2) and NAb titer ( Table 3 ). Seven of the remaining candidate markers showed an association following the published direction of the effect but were not significant after correction for multiple testing. For some of the candidate alleles, the power in our study was very low due to their low frequencies (e.g. previously proposed HLA-DRB1*04:08 was present in only 2.1% of patients). Non-significant associations in the expected directions thus do not imply that these alleles are not associated with NAb presence. Analyses of the secondary EPs showed very similar results (Table 3, Supplementary Tables e-5 and e-6). Overall, quantitative mean NAb titer (EP2) was more strongly associated with candidate variants than binary NAb presence (EP1). This increased sensitivity indicates that the predefined threshold for NAb positivity (20 NU/mL) was not optimally chosen. Indeed, these results suggest that for future genetic association studies, mean antibody titers might be better suited than NAb presence defined by a fixed cut-off.
Discordant results with and among published associations likely arose from different allele frequencies in the investigated populations, different distributions of interferon β preparations in the study cohorts, and different assays for ADA measurement. In general, the heterogeneous geographical and thus genetic background of BENEFIT and BEYOND patients likely led to a decrease in power in our analysis ( Supplementary Figure e-1) . Another reason for observed discrepancies might lie in the assay used. In this study, NAb titers were measured through an MxA induction in vitro assay. In a previous Swedish study, an MxA protein assay, as well as an MxA gene expression assay, was used. 19 In previous German publications, identification of genetic risk alleles was based on ADA titers determined by capture enzyme-linked immunosorbent assay (ELISA) and NAbs assessed by in vivo MxA measurements. 15, 16, 20 In the study on Swedish patients, the HLA-DRB1*15 allele was associated with NAb development in interferon β 1a-treated patients. 19 However, in two previous studies on German patients, not stratified for interferon β preparations, 15, 16 as well as in this analysis, restricted to interferon β-1b, HLA-DRB1*15 was not more common among patients developing ADA ( In a previously published German cohort, the minor allele G of the imputed SNP rs4961252 was associated with higher ADA titers. 20 However, in our international cohort, the SNP was negatively associated with NAbs. The most likely explanation for this phenomenon is a flip-flop effect. 36 Such an effect can occur if a tested candidate marker is a non-causal common variant in weak LD with the unknown real causal variant. Under these circumstances, the effect direction of the candidate variant can reverse due to sampling variation, especially when examining multiethnic populations. This means that rs4961252 is likely not the causal variant, but that it is in weak LD with the actual causal SNP, which remains to be identified.
In addition to analyses on the complete set of patients, we also examined the subset of NAb-positive patients. 
Conclusion
In summary, our study confirms a genetic association of the HLA class II locus with the development of ADA against interferon β-1b. This association was confirmed in both analyses of candidate variants and, indirectly, in hypothesis-free GWAS. Our validation of the importance of the HLA class II locus fits well into the pathophysiologic concept because HLA class II proteins are crucial for antigen presentation to CD4 + T cells that are necessary for inducing the B cell response and subsequent antibody production. In future studies, a larger dataset needs to be examined, including several subsets of genetically homogeneous samples selected from different populations and different interferon β preparations. Importantly, all patients will need to be evaluated using the same assay, ideally both for ADA and for NAbs. These studies will help to elucidate the contribution of genetic variations to ADA development further. The ultimate aim of such analyses should be the establishment of prediction algorithms for ADA development. 
